Stem Cell Treatment for Spinal Cord Injury Passes First Human Safety Trial

Researchers have completed a phase 1 clinical trial — the earliest stage of human testing — using a stem cell product derived from induced pluripotent stem cells (iPSCs), which are adult cells reprogrammed to behave like embryonic ones. The trial focused on patients with subacute complete spinal cord injury (SCI), meaning people in the early weeks after a total loss of function below the injury site. According to Nature Medicine, the study found the treatment to be both clinically feasible and safe over the long term.

The cells used were allogeneic — meaning they came from a donor rather than the patient — and were grown to a clinical grade standard before being used as a neural stem and progenitor cell product. That matters because it means the same batch could potentially be used for multiple patients, rather than having to manufacture a bespoke treatment for each individual.

This is a phase 1 study. It was designed to test safety, not to prove the treatment works — so it cannot yet tell us whether patients regained movement or sensation.

The findings sit within the broader field of regenerative medicine, which aims to repair or replace damaged tissue using biological materials. Spinal cord injury affects thousands of people in the UK each year and currently has no approved treatment that restores lost function, according to NHS guidance. Research of this kind is still at an early stage, and further trials would be needed before any therapy could be considered for routine clinical use.

Kent residents living with spinal cord injury, or their families, can contact their GP or NHS 111 for advice on specialist services and referral pathways. The charity Spinal Research also provides information and support for those affected.